Share

April 10, 2018; 90 (15 Supplement) April 24, 2018

Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies (S20.004)

Qi Zhang, Dustin D. Ruff, Eric M. Pearlman, Sriram Govindan, Sheena K. Aurora
First published April 9, 2018,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 90 no. 15 Supplement S20.004
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 9, 2018.
Copyright & Usage: 
© 2018

Author Disclosures

    1. Qi Zhang1,
    2. Dustin D. Ruff1,
    3. Eric M. Pearlman1,
    4. Sriram Govindan2 and
    5. Sheena K. Aurora1
  1. Qi Zhang1,
  2. Dustin D. Ruff1,
  3. Eric M. Pearlman1,
  4. Sriram Govindan2 and
  5. Sheena K. Aurora1
  1. 1Eli Lilly and Company Indianapolis IN United States
  2. 2Eli Lilly Services India Pvt. Ltd Bengaluru India

Article usage

Article usage: April 2018 to December 2020

AbstractFullPdfSource
Apr 20183400Highwire
May 20188600Highwire
Jun 201810700Highwire
Jul 20186200Highwire
Aug 20187700Highwire
Sep 20189200Highwire
Oct 201818900Highwire
Nov 201813900Highwire
Dec 201810500Highwire
Jan 201912300Highwire
Feb 20196900Highwire
Mar 20197900Highwire
Apr 20195600Highwire
May 20192800Highwire
Jun 20194200Highwire
Jul 20195800Highwire
Aug 20195400Highwire
Sep 20194800Highwire
Oct 20196900Highwire
Nov 20192400Highwire
Dec 2019900Highwire
Jan 20202700Highwire
Feb 20202000Highwire
Mar 20203200Highwire
Apr 20202600Highwire
May 20203400Highwire
Jun 20201100Highwire
Jul 20201100Highwire
Aug 20201300Highwire
Sep 20202700Highwire
Oct 20201100Highwire
Nov 20201300Highwire
Dec 20204200Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me